Admissions and credentials

New York

Experience

Cooley Advises on Keros’ Strategic Review Process, Negotiated Share Repurchase Transactions and Planned Issuer Tender Offer

October 15, 2025

Cooley advised Keros Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its $375 million capital return program, which represents the culmination of Keros’ strategic review process, including its share purchase agreements to repurchase all shares of its common stock beneficially owned by ADAR1 Capital Management and Pontifax Venture Capital and planned tender offer for up to $194 million in value of shares of its common stock.

Read more

Related contacts

Bill Roegge
Partner, New York
Kevin Cooper
Partner, New York
Ryan Sansom
Partner, Boston
Marc Recht
Partner, Boston
Minkyu Park
Special Counsel, New York
Julia Kim
Special Counsel, New York
Kathryn Benvenuti
Associate, New York
Koji Fukumura
Partner, San Diego
Sarah Lightdale
Partner, New York
Craig TenBroeck
Partner, San Diego
Elizabeth Wright
Special Counsel, Boston
Margaux Arntson
Associate
Susan Choy
Associate, New York
Brian P. Golger
Associate, New York
Jill Golub
Associate, New York
Denny Xu
Associate, Boston
Jeffrey J. Tolin
Partner, New York
Reid Hooper
Special Counsel, Washington, DC
Justin Kisner
Special Counsel, San Diego

Related Practices & Industries

Infleqtion to Go Public Through Merger With Churchill Capital Corp X

September 8, 2025

Cooley advised Infleqtion, a global leader in neutral atom-based quantum technology, on its definitive business combination agreement with Churchill Capital Corp X, with the aim to accelerate Infleqtion’s mission to commercialize quantum products that provide orders of magnitude improvement in computing and precision sensing applications.

Read more

Related contacts

Mike Nelson
Partner, Colorado
Garth Angelo Osterman
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Peter Byrne
Partner, New York
Caitlin Breitenbruck
Associate, Seattle
Christine Turner
Associate, Colorado
Won Lee
Associate, Colorado
Ryan Lewis
Associate, Colorado
Orion Armon
Partner, Colorado
Ann Bevitt
Partner, London
Chris Coulter
Partner, London
Ross Eberly
Partner, Santa Monica
David Fletcher
Partner, Washington, DC
Annie Froehlich
Partner, Washington, DC
Todd Gluth
Partner, San Diego
Charles Haley
Partner, Palo Alto
Caroline Hobson
Partner, London
Christopher Kimball
Partner, Washington, DC
Kevin King
Partner, Washington, DC
Barbara Mirza
Partner, Santa Monica
Carly Mitchell
Partner, Washington, DC
Jeremy Morrison
Partner, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Karen Tsai
Special Counsel, Washington, DC
Ryan Bowers
Associate, Washington, DC
Anna Caro
Associate, London
Danielle Carvalho
Associate, Boston
Grady Chang
Associate, Santa Monica
Umer Chaudhry
Associate, Washington, DC
David Dalton
Associate, Santa Monica
Maddie Drabble
Associate, London
Austin Dressen
Associate, Colorado
Megan Drill
Associate, San Diego
Virat Gupta
Associate, Washington, DC
Peter A. Haddad
Associate, San Diego
Elaine Huang
Associate, Palo Alto
Nicollette R. Kirby
Associate, Washington, DC
Andrew Mettry
Associate
Daniel Millard
Associate, London
Emily Mok
Associate, Reston
Juan Nascimbene
Associate, London
Sarah Oliai
Associate, Washington, DC
Emma Plankey
Associate, Boston
Natalie D. Vernon
Associate, Colorado
Brandan Ward
Associate, Colorado
Zi Ye
Associate, Palo Alto
Katherine Duplay
Paralegal Specialist, Colorado
Brandon Lefebvre
Quantitative Analyst, Boston
Kathryn Benvenuti
Associate, New York

Related Practices & Industries

Feedzai Acquires Demyst

April 22, 2025

Cooley advised Feedzai, a global leader in fraud and financial crime prevention, on its acquisition of Demyst, including Demyst’s Zonic data workflow orchestration platform, intellectual property and sophisticated data-integration capabilities.

Read more

Related contacts

Rita Sobral
Special Counsel, London
Kevin Cooper
Partner, New York
Megan Browdie
Partner, Washington, DC
Thomas Connors
Partner, Boston
Annie Froehlich
Partner, Washington, DC
Guadalupe Sampedro
Partner, London
Stella Sarma
Partner, Brussels
Jeffrey J. Tolin
Partner, New York
Ryan Vann
Partner, Chicago
Julia R. Brinton
Special Counsel, Washington, DC
David Hopkins
Special Counsel, Colorado
Kathryn Benvenuti
Associate, New York
Ryan Bowers
Associate, Washington, DC
Athina Gaki
Associate, Brussels
Carly E. Gibbons
Associate, Chicago
Jimmy Gilligan
Associate, Boston
Michael Gladstone
Associate, New York
Eileen Leman
Associate, Los Angeles
Shante Mays
Associate, Reston
Daniel Millard
Associate, London
Shaun (Tianjie) Wang
Associate, New York
Leanne Andrepont
Senior Trademark Paralegal
Patricia Myers
Paralegal Specialist, Colorado

SKIMS Acquires SKKN by Kim From Kim Kardashian and Coty

March 21, 2025

Cooley advised Kim Kardashian, an American media personality, socialite and businesswoman, on SKIMS’ acquisition of SKKN by Kim, a beauty, skincare, and fragrance brand she founded, including the 20% stake held by Coty.

Read more

Related contacts

Dave Young
Partner, Santa Monica
Julia Kim
Special Counsel, New York
Kyle Hess
Associate, New York
Kathryn Benvenuti
Associate, New York
Mark Cikowski
Associate, Santa Monica
Adam Chase
Partner, Washington, DC
Kimberly Nguyen
Special Counsel, Reston
Liz Paisner
Associate, New York
Stephanie Gentile
Partner, New York
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Calvin Lee
Associate, New York
John Paul Oleksiuk
Partner, New York
Ross Eberly
Partner, Santa Monica
Austin Holt
Partner, Santa Monica
Bram G. Couvreur
Partner, Santa Monica
Michael Klein
Partner, New York
Michael Neumeister
Partner, Los Angeles
Robert Eisenbach
Of Counsel, San Francisco
Jessica Girone
Associate, Santa Monica

Related Practices & Industries

Cooley Advises Special Committee of Checkpoint on Acquisition by Sun Pharma

March 9, 2025

Cooley advised the special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for up to $416 million in cash and contingent value rights.

Read more

Related contacts

Bill Roegge
Partner, New York
Kevin Cooper
Partner, New York
Marc Recht
Partner, Boston
Wesley Dietrich
Associate, Washington, DC
Kathryn Benvenuti
Associate, New York
Michael Bergmann
Partner, Washington, DC
Eileen Marshall
Partner, Washington, DC
Alan W. Tamarelli
Partner, New York
Julia R. Brinton
Special Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Stella Sarma
Partner, Brussels
Natasha Leskovsek
Of Counsel, Washington, DC
Karun Ahuja
Special Counsel, Chicago
Matthew Choy
Associate, New York
Jameson Davis
Associate, Boston
Kyle Hess
Associate, New York
Allison Kutner
Associate, New York
Breanna Qin
Associate, Palo Alto
Arda Can Tekin
Associate, London
Ryan Vann
Partner, Chicago

Related Practices & Industries

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.